GNS Healthcare announced today a major expansion of its senior management team, positioning the company for substantial growth in the deployment of its offerings across the healthcare industry.  Carol McCall has been named Chief Strategy Officer and David Burke has been named Chief Operating Officer and Chief Financial Officer, effective immediately.

GNS Healthcare announced a collaboration with David W. Bates, MD, M.Sc. and Brigham and Women’s Hospital (BWH), a teaching affiliate of Harvard Medical School. Their collaboration will initially focus on predicting adverse drug events and on hospital readmissions for patients admitted for congestive heart failure.

GNS Healthcare enters a collaboration with Bristol-Myers Squibb focused on the discovery of novel disease biology and biomarkers in the area of immuno-inflammation.

GNS is collaborating with the National Cancer Institute (NCI) to accelerate lung cancer research with a supercomputing platform that can rapidly uncover cause-and-effect mechanisms hidden in huge data sets assembled from imaging, genetics, pathology, and other areas.

GNS Healthcare announces the publication of results from a study focused on identifying novel drug targets for the one-third of rheumatoid arthritis patients who do not respond to leading anti-TNF therapies.

GNS Healthcare has announced that it has entered into a joint venture with Berg Biosystems, focusing on drug repositioning through unlocking drug mechanisms.

GNS Healthcare has announced that it has entered into a contract with the National Cancer Institute (NCI) and SAIC-Frederick to unravel the mechanisms of several well-known cancer treatments.

GNS announces a two-year collaboration with Brigham and Women’s Hospital (BWH), a teaching affiliate of Harvard Medical School. The goal of the collaboration is to identify biomarkers to predict patient response to asthma therapies and to discover new biology that may lead to better treatments for asthma.

Gene Network Sciences GNS announced that it has signed a drug development contract with Johnson & Johnson Pharmaceutical Research & Development to use data-driven computer models to help determine the pathways associated with the mechanism of action, biomarkers and tumor specificity of a pre-clinical oncology compound.